EVOTEC SEINH O.N. news, videos and press releases - Page 5
For more news please use our advanced search feature.
EVOTEC SEINH O.N. - More news...
EVOTEC SEINH O.N. - More news...
- Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme
- EQS-News: Evotec SE Annual General Meeting 2023 approves all proposed agenda items
- Evotec SE Annual General Meeting 2023 Approves All Proposed Agenda Items
- EQS-News: Evotec presents sustainability strategy
- Evotec Presents Sustainability Strategy
- EQS-News: Evotec receives grant from Open Philanthropy for discovery of RNA-targeting Henipavirus therapeutics
- Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics
- EQS-News: Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023
- Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023
- EQS-News: Just – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing
- EQS-Adhoc: Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz
- Just - Evotec Biologics Enters Strategic Biosimilars Partnership with Sandoz
- Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing
- EQS-News: Evotec SE provides update on cyber attack
- Evotec SE Provides Update on Cyber Attack
- EQS-Adhoc: Cyber Attack on Evotec
- Cyber Attack on Evotec
- EQS-News: Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
- EQS-Adhoc: Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
- Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership
- EQS-News: Evotec SE preliminary fiscal year 2022 results: 'Ahead of the curve' – very strong performance in a challenging year
- Evotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging Year
- EQS-News: Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis
- Evotec Receives US$ 6.6 m Grant for Drug Discovery in Tuberculosis
- EQS-News: Evotec SE to announce preliminary financial results for fiscal year 2022 on 28 March 2023
- Evotec SE to Announce Preliminary Financial Results for Fiscal Year 2022 on 28 March 2023
- EQS-News: Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb
- Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
- EQS-News: Evotec receives € 150 m loan from European Investment Bank
- Evotec Receives € 150 m Loan from European Investment Bank
